Bullous pemphigoid/ Huge blister / Blister size of a quarter / Little blisters / Blisters in throath; This spontaneous case was reported by a patient and describes the occurrence of PEMPHIGOID (Bullous pemphigoid/ Huge blister / Blister size of a quarter / Little blisters / Blisters in throath) in a 76-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 007521-2A, 066021A, 013M20A and 026L20A) for COVID-19 vaccination.     The patient had no allergy.  The patient's past medical history included Transplant (2 transplant). Concurrent medical conditions included Immunocompromised, Diabetes and Gastroparesis.   On 27-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 24-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 15-Aug-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 04-Feb-2022, received fourth dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced PEMPHIGOID (Bullous pemphigoid/ Huge blister / Blister size of a quarter / Little blisters / Blisters in throath) (seriousness criterion medically significant). The patient was treated with PREDNISONE at an unspecified dose and frequency. At the time of the report, PEMPHIGOID (Bullous pemphigoid/ Huge blister / Blister size of a quarter / Little blisters / Blisters in throath) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 19-Aug-2022, SARS-CoV-1 test: (Positive) Positive. On an unknown date, Biopsy: The result was bullous pemphigoid..         The patient received antibodies to protect against COVID-19. The concomitant  medication was not reported. On 11-JUn-2022, the patient had huge bister as a size of the quarter. The dermatologist performed a biopsy and diagnosed as  bullous pemphigoid. The patient had more blisters around that big one and recently had blisters on throat. The patient wen to pharmacy and provided by mouth wash.  The patient researched online and thought that might have autoimmune blistering disease. This symptoms was reported previously for Pfizer and eager to know whether this happened with Moderna. The patient would like to know whether could receive new Moderna booster and need to be provided with some more information regarding blisters.  Company comment: This is a spontaneous case concerning a 76 years-old female patient with reported relevant medical history of immunodeficiency, who experienced the unexpected and serious (due to medically significant) event of pemphigus. The event occurred after a booster dose of Covid-19 vaccine with mRNA-1273 vaccine. Patient stated that on 11 June 2022 she noted a huge blister with the size of a quarter. She visited a dermatologist and biopsy was performed  result showed bullous pemphigus. She started treatment with Prednisolone. Later she had developed more blisters around the first one including on her throat. She received a mouth wash from the pharmacy for that.  No further information disclosed about diagnostic tests performed or treatments received. At the time of the report, the outcome of the event was unknown. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report.   This case was linked to MOD-2022-660014 (Patient Link).; Sender's Comments: This is a spontaneous case concerning a 76 years-old female patient with reported relevant medical history of immunodeficiency, who experienced the unexpected and serious (due to medically significant) event of pemphigus. The event occurred after a booster dose of Covid-19 vaccine with mRNA-1273 vaccine. Patient stated that on 11 June 2022 she noted a huge blister with the size of a quarter. She visited a dermatologist and biopsy was performed  result showed bullous pemphigus. She started treatment with Prednisolone. Later she had developed more blisters around the first one including on her throat. She received a mouth wash from the pharmacy for that.  No further information disclosed about diagnostic tests performed or treatments received. At the time of the report, the outcome of the event was unknown. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report.